Key result
The highest quartile of plasma PAF-AH activity was associated with a 1.8-fold increased risk of coronary artery disease compared with the lowest quartile.
Why the study?
Is higher plasma PAF-AH activity associated with an increased risk of coronary artery disease and inflammatory markers?
Cross-Sectional (n=973)
Is higher plasma PAF-AH activity associated with an increased risk of coronary artery disease and inflammatory markers?
Higher plasma PAF-AH activity is associated with an increased risk of coronary artery disease, particularly in patients not receiving statins or ACE inhibitors, independent of common inflammatory markers.
Answers are grounded in this paper and cite their sources.
Higher PAF-AH activity may mark CAD risk independent of inflammation; leaves open whether it is causal or a biomarker.
Inflammation underlies both onset and perpetuation of atherosclerosis. Plasma lipoproteins transport the platelet-activating factor-acetylhydrolase (PAF-AH) with potentially anti-inflammatory activities. Our aim was to determine whether PAF-AH activity was associated with inflammatory markers and with coronary artery disease (CAD). PAF-AH activity and a panel of inflammatory mediators were measured in plasma of 496 patients with CAD and in 477 controls; 276 patients presented with stable angina pectoris and 220 with acute coronary syndrome (ACS). Individuals within the highest quartile of PAF-AH activity had an 1.8-fold increase in CAD risk [95% confidence interval (CI), 1.01 to 3.2; P = 0.048] compared with those in the first quartile (adjusted for clinical and metabolic factors). When excluding individuals receiving statin and angiotensin-converting enzyme-inhibitor medication, individuals within the highest quartile of PAF-AH activity revealed a 3.9-fold increase in CAD risk (95% CI, 2.0 to 7.7; P < 0.0001). In these subjects, the plasma PAF-AH activity increased gradually in stable angina and in ACS both in men (P < 0.0001) and in women (P < 0.001), as compared with controls. No correlation was found between PAF-AH levels and those of common markers of inflammation. This study and the previous ones raise the important issue of whether PAF-AH is simply a marker of risk or directly promotes atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Blankenberg et al. (2003) conducted a cross-sectional in Coronary artery disease (n=973). Highest quartile of PAF-AH activity vs. First quartile of PAF-AH activity was evaluated on Coronary artery disease risk (OR 1.8, 95% CI 1.01-3.2, p=0.048). The highest quartile of plasma PAF-AH activity was associated with a 1.8-fold increased risk of coronary artery disease compared with the lowest quartile.
Synapse has enriched 10 related papers. Consider them for comparative context: